We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.
|Original language||English (US)|
|Number of pages||5|
|Journal||Radiotherapy and Oncology|
|State||Published - Nov 2006|
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
- Lung cancer